品名：Seraseq® gDNA TMB Reference Panel Mix

货号：0710-2463

品牌：SeraCare 

Details

The level of somatic mutations in a tumor, called tumor mutational burden (TMB), is used as a biomarker to 

predict patient response to immune checkpoint inhibitor therapy, with cancer type-specific TMB cut-offs of 

clinical value. Whole exome sequencing (WES) has been the gold standard to measure TMB. While targeted 

panels have the capacity to estimate TMB, TMB scores can vary significantly depending on the panel size, 

coverage regions, and bioinformatics pipeline used to make variant calls. LGC SeraCare has developed Seraseq 

gDNA TMB Reference Panel Mix, which has been extensively validated using WES and can be used to guide 

TMB score assessment using targeted panels, especially around values that may be clinical decision points for 

different tumor types. Each Seraseq gDNA TMB Reference Panel Mix contains five vials of purified genomic 

DNA from tumor-like human cell lines encompassing complex genomic signatures over a broad range of TMB 

scores, all in one kit.

维百奥生物代理SeraCare对照及参比物质。

维百奥（北京）生物科技有限公司，自2018年与SeraCare（现隶属于LGC Clinical Diagnostics）合作以来，长期为中国客户

提供包括SeraSeq系列参比物质，领域包括肿瘤、生殖健康和遗传病。SeraCare研发和生产一系列临床参比物质，可以用于任何

研发阶段，以确保临床基因组学检测结果的准确性。

SeraCare参比物质涵盖的范围：

1）Next Generation Sequencing

2）Sanger Sequencing

3）Real-time PCR and digital PCR (dPCR)

4）Microarray

主要特点

1）Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs, 

and RNA fusions

2）Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs

3）Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA 

in plasma, and FFPE

4）Manufactured in cGMP-compliant, ISO 13485-certified facilities

5）Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers